Open Nav

MyopiaCure

  • Suh-Hang (Hank) Juo, MyopiaCure

fundraising, find strategic partners

  • Date:Wednesday, October 17
  • Time:4:00 PM - 4:15 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Myopia (also known as nearsightedness) has become a pandemic eye disease, with an annual global market size of over 67 billion USD. Myopia increases the risk for severe eye complications, and myopia is the leading cause of blindness in Asia. Currently, atropine is the only effective drug to stop myopia progression but atropine has several side effects. There is a high demand for an effective and non-invasive treatment to stop myopia. We have identified a small molecule causing myopia. We have developed a novel patented drug in eyedrop form to cure myopia. The therapeutic effects have been demonstrated in in-house rodent and non-rodent animal studies and confirmed by an independent third party CRO company. Our drug is 3x more effective than atropine, and does not show side effects. The toxicology study also shows no adverse effects. We plan to file IND in 12 months and finish the phase IIa study in 5 years. Our mission is to develop novel and effect eyedrop to stop myopia progression.
  • Company Website:https://www.tsi.center/en/portfolio-item/cmu-anti-myopia-eyed
  • Company HQ City:Taipei
  • Company HQ Country:Taiwan
  • Year Founded:to be founded in 2019
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development :eyedrop
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Organization Description/Mission Statement:Myopia (also known as nearsightedness) has become a pandemic eye disease, with an annual global market size of over 67 billion USD. Myopia increases the risk for severe eye complications, and myopia is the leading cause of blindness in Asia. Currently, atropine is the only effective drug to stop myopia progression but atropine has several side effects. There is a high demand for an effective and non-invasive treatment to stop myopia. We have identified a small molecule causing myopia. We have developed a novel patented drug in eyedrop form to cure myopia. The therapeutic effects have been demonstrated in in-house rodent and non-rodent animal studies and confirmed by an independent third party CRO company. Our drug is 3x more effective than atropine, and does not show side effects. The toxicology study also shows no adverse effects. We plan to file IND in 12 months and finish the phase IIa study in 5 years. Our mission is to develop novel and effect eyedrop to stop myopia progression.
  • Organization HQ City:Taipei
  • Organization HQ Country:Taiwan
  • Total Amount Raised to Date, In All Rounds:1.2 million
Speakers
Suh-Hang (Hank) Juo
MyopiaCure
Back